Home Featured Page 275

Featured

Latest

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Karina Bashir on Psychedelics, Islam, and Human Rights

PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney...

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

The Effects of Antidepressant Discontinuation on MDMA-Assisted Psychotherapy

Should You Listen to Music During Psychedelic Treatments? How Sounds Impact...

Will the Biden Administration Embrace Federal Psychedelic Reform?

Center for Psychedelic Medicine Established at NYU Langone Health

So, You Want to Take Ibogaine: Here’s What You Need to...

Red Light Holland Announces Closing of $11.6 Million Bought Deal Financing

1...274275276...293 Page 275 of 293

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Karina Bashir on Psychedelics, Islam, and Human Rights

PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney...

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

The Effects of Antidepressant Discontinuation on MDMA-Assisted Psychotherapy

Should You Listen to Music During Psychedelic Treatments? How Sounds Impact...

Interview With Christi Myers

Interview With Ronan Levy

Will the Biden Administration Embrace Federal Psychedelic Reform?

Center for Psychedelic Medicine Established at NYU Langone Health

So, You Want to Take Ibogaine: Here’s What You Need to...

Red Light Holland Announces Closing of $11.6 Million Bought Deal Financing

EDITOR PICKS

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY